Epidermolysis Bullosa TherapeuticsMarket – Regional Analysis
On the basis of region, theglobal EpidermolysisBullosa Therapeutics Market is segmented into North America, Latin America,Europe, Asia Pacific, Middle East, and Africa.
Epidermolysis Bullosa (EB) is arare, genetic disorder of skin tissues. People suffering from EB have fragileskin, which is susceptible to blisters leading to wounds that are difficult toheal. Symptoms related to this disorder includes, blistering of skin, deformityor loss of fingernails and toenails, internal blistering including on thethroat, esophagus, stomach, intestines and urinary tract, skin thickening onpalms and soles of the feet (hyperkeratosis) and scalp blistering, scarring,and hair loss (scarring alopecia).
Epidermolysis BullosaTherapeutics Market Drivers
Development of various pipelinedrugs for treatment of EB is a major factor expected to drive the epidermolysisbullosa therapeutics market growth. For instance, Fibrocell Technologies, Inc.is undergoing clinical trial for its drug FCX-007 for the treatment of EB. Thisdrug is under clinical phase II and is expected to be completed in December2033.
Moreover, TWi Biotechnology, Inc.is conducting phase II clinical trial for the drug AC-203 to treat skin lesionsin EB and is expected to complete the study in February 2019.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2214
Furthermore, Amryt ResearchLimited is conducting clinical trial phase III for its drug Oleogel-S10, whichis intended for the treatment of wounds in EB that is expected to complete inSeptember 2020.
Furthermore, in May 2018, AbeonaTherapeutics Inc. announced updated clinical data from the Phase I/II trial ofEB-101, a gene-corrected skin graft cell therapy for patients suffering fromrecessive dystrophic epidermolysis bullosa (RDEB). The EB-101 has been grantedRegenerative Medicine Advanced Therapy (RMAT) designation in January 2018,Orphan Drug Designation and Rare Pediatric Disease Designation from the US Foodand Drug Administration (US FDA) and European Medicines Agency (EMA) in 2017.
Therefore, large number of drugsin the pipeline is providing growth opportunities for the players inepidermolysis bullosa therapeutics market during the forecast period.
Epidermolysis BullosaTherapeutics Market Restraints
Withdrawal of drugs failing tomeet expectations is expected to restrain growth of EB therapeutics market. Forinstance, in September 2017, Rival Amicus Therapeutics, withdrew its AP101 drugwhich was in phase III clinical study. AP101 drug was a water based cream,which is only supposed to be applied when dressings are changed every three orfour days, as recommended for EB patients. Such water-based cream requiredpatients to change dressings daily and the company indicated this might be thereason for its failure to hit targets for wound closure in patients withinthree months.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/epidermolysis-bullosa-therapeutics-market-2214
North America region is expectedto witness growth in the EB therapeutics market due to inorganic growthstrategies adopted by key players. For instance, in August 2015, AmicusTherapeutics, a biotechnology company involved in developing drugs for orphandiseases acquired Scioderm, Inc., a company involved in developing innovativetherapies for treating diseases. This acquisition aims to accelerate clinicaldevelopment of Zorblisa, drug of Amicus Therapeutics, which is underpreclinical investigation for commercialization, for the treatment ofepidermolysis bullosa.
Strategies used by key playerssuch as collaboration in Asia Pacific region is also expected to drive growthof the EB therapeutics market in the region. For instance, in August 2018,RegeneRx Biopharmaceuticals, Inc., entered into a joint venture with YuYangDNU, a Korean company to develop its product- RGN-137 on a global basis for theorphan indication, epidermolysis bullosa (EB) which is under preclinical study.Furthermore, YuYang will invest about US$17.8 million in cash for its clinicaldevelopment.
Key players operating inepidermolysis bullosa therapeutics market include Birken AG, Fibrocell Science,Inc., RegeneRx Biopharmaceuticals, Inc., GlaxoSmithKline Plc., InMedPharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V.,Scioderm, Inc., Stratatech Corporation, TWi Biotechnology Inc., Amryt ResearchLimited, and WAVE Life Sciences Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2214
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
